Study S002758

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT06628362
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 447
Start: 2024-11-21
Primary completion: 2026-05-29
Lead sponsor: Carmot Therapeutics, Inc.
Conditions: Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:Placebo; DRUG:Enicepatide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:XC45544

Registered primary outcomes

Percent Change in Body Weight from Baseline to Week 36 [Baseline to Week 36]
Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36 [Baseline to Week 36]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0052201	763-P: Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes ALEXANDRA STEINBERG, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06628362